Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Oman Healthcare News.
Press releases published on September 16, 2025
Strata Acquires Keystone Perfusion, Creating Integrated Organ Recovery Platform, Diversifying into Other Medical Services
Keystone is expected to generate approximately $65 million of revenue and approximately $13 million of Adjusted EBITDA(1) in the full-year 2025, with revenue expected to grow more than 50% in 2025 versus 2024 Acquisition follows multi-year partnership …
PolyPid Successfully Completes Israeli Ministry of Health GMP Inspection, Advancing Towards Commercial Manufacturing Readiness for D-PLEX₁₀₀
PETACH TIKVA, Israel, Sept. 16, 2025 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD) ("PolyPid" or the "Company"), a late-stage biopharma company aiming to improve surgical outcomes, today announced the successful completion of a routine Good Manufacturing …
BrainsWay Receives FDA Clearance for Accelerated Deep TMS Protocol for Non-Invasive Treatment of Major Depressive Disorder (MDD)
Clinical data shows that BrainsWay’s new accelerated stimulation protocol is comparable to standard Deep TMS in depression score improvement, response and remission The accelerated protocol is now commercially available in the United States, expanding …
TOMI Environmental Solutions to Participate in the iAccess Alpha Virtual Best Ideas Fall Investment Conference 2025 on September 16–17, 2025
FREDERICK, Md., Sept. 16, 2025 (GLOBE NEWSWIRE) -- TOMI Environmental Solutions, Inc.® (“TOMI”) (NASDAQ: TOMZ), a global company specializing in disinfection and decontamination utilizing its premier Binary Ionization Technology (BIT) platform through its …
Jyong Biotech Announces Completion of Patient Enrollment of over 700 subjects in Phase II Clinical Trial of MCS‑8 for Prostate Cancer Prevention
New Taipei City, Taiwan, Sept. 16, 2025 (GLOBE NEWSWIRE) -- Jyong Biotech Ltd. (Nasdaq: MENS) (the “Company”, “Jyong Biotech”), a science-driven biotechnology company based in Taiwan committed to developing and commercializing innovative and differentiated …
Silo Pharma Announces Initial Investment in Ethereum and Solana under Cryptocurrency Treasury Strategy
Strategic capital deployment advances Company’s blockchain treasury model and biopharma development initiatives SARASOTA, FL, Sept. 16, 2025 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (Nasdaq: SILO) (“Silo” or the “Company”), a diversified developmental-stage …
SCIENTURE Secures PBM-Led GPO Rebate Agreement to Drive Expanded Commercial Coverage and Formulary Access for Arbli™(losartan potassium) in the $256M U.S. Losartan Market
Arbli™ is the first and only ready-to-use liquid formulation of losartan, eliminating the need for compounding while offering reduced dosing volume and extended room-temperature shelf life COMMACK, NY, Sept. 16, 2025 (GLOBE NEWSWIRE) -- SCIENTURE HOLDINGS, …
Autolus Therapeutics to Present Clinical Data Update at the American College of Rheumatology (ACR) Convergence 2025
LONDON and GAITHERSBURG, Md., Sept. 16, 2025 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), an early commercial-stage biopharmaceutical company developing, manufacturing and delivering next-generation programmed T cell therapies, announces …
KFSHRC reduziert Wartezeit für Betten in der Notaufnahme um 75 %
RIAD, Saudi-Arabien, Sept. 16, 2025 (GLOBE NEWSWIRE) -- Das King Faisal Specialist Hospital and Research Centre (KFSHRC) in Riad hat die durchschnittliche Wartezeit in der Notaufnahme von über 13 Stunden im Jahr 2023 auf nur noch 3,2 Stunden bis Mitte 2025 …
KFSHRC réduit de 75 % le temps d’attente aux urgences pour obtenir une hospitalisation
RIYAD, Arabie saoudite, 16 sept. 2025 (GLOBE NEWSWIRE) -- Le King Faisal Specialist Hospital and Research Centre (KFSHRC) à Riyad a réduit le temps d’attente médian aux urgences, qui est passé de plus de 13 heures en 2023 à seulement 3,2 heures au milieu …
HCW Biologics Designates One of Its Proprietary TRBC-Pembrolizumab-Based Immune Checkpoint Inhibitors as its Franchise Immunotherapeutic for Internal Clinical Development
Lead product candidate will be advanced to late IND-enabling studies to prepare for clinical trials for evaluation in the treatment of solid tumors Discovery of unique combination of cytokines in multi-functional fusion protein molecule that exhibits …
SpyGlass Pharma Appoints Anand Sundaram as Head of Commercial
ALISO VIEJO, Calif., Sept. 16, 2025 (GLOBE NEWSWIRE) -- SpyGlass Pharma, a late-stage biopharmaceutical company, today announced the appointment of Anand Sundaram as the company’s Vice President, Head of Commercial. Mr. Sundaram brings over a decade of …
Hyperion DeFi Enters Into First HAUS Agreement With Proprietary Trading Firm Credo
LAGUNA HILLS, Calif., Sept. 16, 2025 (GLOBE NEWSWIRE) -- Hyperion DeFi, Inc. (NASDAQ: HYPD) (“Hyperion DeFi” or the “Company”), the first U.S. publicly listed company building a long-term strategic treasury of Hyperliquid’s native token, HYPE, today …
Medicines360 acquires global rights to PeriPeach™, advancing new maternal health technology through the 360 Innovation Hub™
SAN FRANCISCO, Sept. 16, 2025 (GLOBE NEWSWIRE) -- Medicines360, a women’s health innovation organization with a mission to be a catalyst for change, today announced that it has acquired global licensing rights to PeriPeach, an investigational medical …
Starton Therapeutics Granted New U.S. Patent #12,390,457 Titled “Stable Solutions of Immunomodulatory Imide Compounds for Parenteral Use” a Formulation of STAR-LLD
New U.S. patent provides IP coverage for the formulation to 2042 Further expands Starton’s intellectual property portfolio surrounding its lead product candidate, STAR-LLD, Method of Use Patent #11,197,852 which provides IP coverage to 2040 PARAMUS, N.J., …
Parexel Announces Appointment of Rob Goodwin as Chief Operating Officer
RALEIGH, N.C., Sept. 16, 2025 (GLOBE NEWSWIRE) -- Parexel, a leading global clinical research organization (CRO) providing insights-driven Clinical and Consulting solutions to the world’s life sciences industry, today announced the appointment of Rob …
Avadel Pharmaceuticals Celebrates Five Years of Driving Growth in Sleep Research Funding
A Media Snippet accompanying this announcement is available by clicking on this link. DUBLIN, Sept. 16, 2025 (GLOBE NEWSWIRE) -- The American Academy of Sleep Medicine Foundation (AASM Foundation) and Avadel Pharmaceuticals are celebrating five years of …
FDA Grants Fast Track Designation to Corbus Pharmaceuticals’ Nectin-4 Targeting ADC CRB-701 in Head and Neck Squamous Cell Carcinoma
Dose optimization data from the Phase 1/2 study to be presented next month at ESMO 2025 Second Fast Track designation granted by FDA for CRB-701 NORWOOD, Mass., Sept. 16, 2025 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“ …
ORYZON Strengthens Patent Portfolio for Iadademstat and Vafidemstat with New Decisions to Grant
MADRID and CAMBRIDGE, Mass., Sept. 16, 2025 (GLOBE NEWSWIRE) -- Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a clinical-stage biopharmaceutical company and a European leader in epigenetics, today announced that it continues to expand its patent …
Marine Biologics Partners with Molecular Quantum Solutions to Accelerate Next-Generation Biomaterials Development
BERKELEY, Calif. and COPENHAGEN, Denmark, Sept. 16, 2025 (GLOBE NEWSWIRE) -- Biomaterials company Marine Biologics today announced an exclusive strategic partnership with Molecular Quantum Solutions (MQS) in which Marine Biologics will be the sole …